Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 17 cze 2022 · The EASL Clinical Practice Guidelines (CPGs) on the management of hepatic encephalopathy (HE) present evidence-based answers to a set of relevant questions (where possible, formulated in PICO [patient/population, intervention, comparison and outcomes] format) on the definition, diagnosis, differential diagnosis and treatment of HE.

  2. Hepatic encephalopathy (HE) is a common reversible neuropsychiatric syndrome associated with chronic and acute liver dysfunction and significant morbidity and mortality. Although a clear pathogenesis is yet to be determined, elevated ammonia in the ...

  3. 2 mar 2020 · Key points. •. Both subclinical and overt hepatic encephalopathy predict a poor prognosis. •. Risk factors for a poor prognosis include acid-base and electrolyte disturbances, diminished renal function, biochemical evidence of poor hepatic synthetic function, and acute-on-chronic liver failure. •.

  4. 6 kwi 2018 · Hepatic encephalopathy (HE) is not synonym of delirium/coma in a subject with end-stage liver disease; rather it is a specific condition with its own pathophysiology. Once diagnosed, it requires a multiaxial assessment and classification.

  5. Prognosis of hepatic encephalopathy is guarded, in spite of improvement in intensive medical support. One-year survival is 40%, and 3-year survival is 15%. Fulminant hepatic failure has a mortality rate of 75%, and severe hepatic coma carries a substantial risk of permanent neurologic disability.

  6. 22 cze 2024 · The objective of this consensus report is to provide up-to-date knowledge about the epidemiology, pathophysiology, clinical presentation, and recommendations for the diagnosis, treatment, and prevention of diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) in adults.

  7. 1 maj 2021 · HD is associated with a higher risk of developing hepatic decompensations, such as ascites, variceal bleeding, hepatic encephalopathy, renal dysfunction, refractory ascites, and hepatocellular carcinoma along with reduced survival rates than normoglycemic patients with cirrhosis of liver.